Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia.

NCT00267267 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00267267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00267267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia.
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2006
Completion date
January 31, 2007
Enrollment
1,784
Sites
123

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemia, hyperlipidemia